The role of chemotherapy in the treatment of malignant astrocytomas

Canadian Journal of Neurological Sciences

Volumn 33, Issue 2, 2006, Pages 127-140

  Mathieu, David ^a   Fortin, David ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; 6 O BENZYLGUANINE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTICONVULSIVE AGENT; BIOLOGICAL PRODUCT; CARBOPLATIN; CARMUSTINE; CISPLATIN; COLCHICINE; CYCLOSPORIN; CYTOTOXIC AGENT; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; HYDROXYUREA; IRINOTECAN; LOMUSTINE; NIMUSTINE; NITROSOUREA DERIVATIVE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PRINOMASTAT; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN; UNINDEXED DRUG; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ACNE VULGARIS; ASTROCYTOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL TUMOR; CONSTIPATION; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG ISOLATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRY SKIN; ENCAPSULATION; FATIGUE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HEADACHE; HEART FAILURE; HEMATOLOGIC DISEASE; HOT FLUSH; HUMAN; INFECTION; LEUKOPENIA; LUNG FIBROSIS; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MUCOSA INFLAMMATION; MUCOSAL DRYNESS; MULTIDRUG RESISTANCE; MUSCULOSKELETAL DISEASE; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OLIGODENDROGLIOMA; OTOTOXICITY; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RECURRENT DISEASE; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; TOXICITY; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 33744913014     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100004881     Document Type: Review

References (159)

1. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. International Histological Classification of Tumours. Geneva, Switzerland, World Health Organization, 1995.
2. Daumas-Duport C, Varlet P, Tucker M-L, et al. Oligodendrogliomas: Part 1-Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J Neurooncol. 1997; 34:37-59.
3. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia. 1995; 15:211-221.
4. Alvord EC. Is necrosis helpful in the grading of gliomas? Editorial opinion. Neuropathol Exp Neurol. 1992; 51:127-32.
5. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000; 6:2585-97.
6. Giles GG, Gonzales MF. Epidemiology of brain tumors and factor in prognosis. In: Kaye AH, Laws ER, editors. Brain tumours, an encyclopedic approach. London: Churchill Livingstone; 2001, p. 51-70.
7. Silbergeld DL, Chicoine MR. Isolation and characterization of human malignant glioma cells from histologically normal brain. J Neurosurg. 1997; 86:525-31.
8. Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. 1998; 18:1303-12.
9. Huncharek M, Muscat J, Geschwing JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis. Anticancer Res. 1998; 18:4693-8.
10. Buatti JM, Marcus RB, Mendenhall WM, Friedman WA, Boya FJ. Accelerated hyperfractionated radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys. 1996; 34:785-92.
11. Shin KH, Muller PJ, Geggie PHS. Superfractionation radiation therapy in the treatment of malignant astrocytoma. Cancer. 1983; 52:2040-3.
12. Laperriere N, Zuraw L, Cairncross G. The Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group: radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002; 64:259-73.
13. Brandes AA, Pasetto LM, Monfardini S. New drugs in recurrent high grade gliomas. Anticancer Res. 2000; 20:1913-20.
14. Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol. 2000; 18:1481-91.
15. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. Procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000; 83:588-93.
16. Stupp R, Mason W, van de Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352:987-96.
17. Fortin D. Altering the properties of the blood-brain-barrier: disruption and permeabilization. In: Prokai L, Prokai-Tatrai K, editors. Peptide transport and delivery into the central nervous system. Basel: Birkhauser; 2003. p. 127-54.
18. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49:333-43.
19. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303:1323-9.
20. Van den Bent MJ. Chemotherapy in adult malignant glioma. Front Radiat Ther Oncol. 1999; 33:174-91.
21. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Metaanalysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993; 71:2585-97.
22. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002; 359:1011-8.
23. Levin VA. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are healing. Neuro-Oncol. 1999; 1:69-80.
24. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology. 2004; 63:1281-4.
25. Levin VA, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18:321-4.
26. Fortin D, Cairncross JG, Hammond RR. Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery. 1999; 45:1279-91.
27. Prados MD, Scott C, Curran WJ, et al. Procarbazine, Lomustine and Vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol. 1999; 17:3389-95.
28. Medical Research Council Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytomas: a Medical Research Council Trial. J Clin Oncol. 2001; 19:509-18.
29. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999; 17:409-22.
30. O'Duyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs. 2000; 5984:19-27.
31. Selvaratnam G, Philips RH, Mohamed AK, Radzi A. Adverse effects of cytotoxics-platinum agents. Adverse Drug React Toxicol Rev. 1997; 16:171-97.
32. Prados MD, Warnick RE, Mack EE, et al. Intravenous carboplatin for recurrent gliomas. Am J Clin Oncol. 1996; 19:609-12.
33. Twelves CJ, Ash CM, Miles DW, Thomas DGT, Souhami RL. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol. 1991; 27:481-3.
34. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 1994; 19:69-74.
35. Yung WKA, Mechitler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol. 1991; 9:860-4.
36. Huncharek M, Kupelnick B, Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev. 1998; 24:307-16.
37. Lunardi P, Farah JO, Mastronardi L, Puzzilli F, Lo Bianco FM. Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study. Acta Neurochir. 1996; 138:215-20.
38. Choi IS, Lee SH, Kim TY, et al. Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2002; 60:171-6.
39. Brandes AA, Pasetto LM, Vastola F, Monfardini S. Temozolomide in patients with high grade gliomas. Oncology. 2000; 59:181-6.
40. Newlands ES, Stevens FG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997; 23:35-61.
41. Friedman HS. Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. Semin Oncol. 2000; 27:35-40.
42. Yung WKA. Temozolomide in malignant gliomas. Sem Oncol. 2000; 27:27-34.
43. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997; 40:484-8.
44. Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 17:2762-71.
45. Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer. 2000; 36:1788-95.
46. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of Temozolomide using an extended continuous oral schedule. Cancer Res. 1998; 58:4363-7.
47. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro-oncol. 2002; 4:39-43.
48. Prados MD. Future directions in the treatment of malignant gliomas with temozolomide. Sem Oncol. 2000; 27:41-6.
49. Stupp R, Dietrich P, Kraljevic SO, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002; 20:1375-82.
50. Athanassiou H, Synodinou M, Maragoudakis E, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005; 23:2372-7.
51. Hande KR. Etoposide pharmacology. Sem Oncol. 1992; 19 S13:3-9.
52. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998; 34:1514-21.
53. Simon J. The clinical pharmacology of etoposide: an update. Cancer Treat Rev. 1996; 22:179-221.
54. Kobayashi Ratain MJ. New perspectives on the toxicity of etoposide. Semin Oncol. 1992; 19 S13:78-83.
55. Kiya K, Uozumi T, Ogasawara H, et al. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer Chemother Pharmacol. 1992; 29:339-42.
56. Beauchesne P, Bonner JA, Mornex F, Brunon J. Étude de la sensibilité à l'étoposide de lignées humaines de gliomes malins. Mécanismes d'action. Cancer Radiother. 1999; 3:57-64.
57. Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol. 1992; 10:1074-7.
58. Franceschi E, Cavallo G, Scopece L, et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer. 2004; 91:1038-44.
59. Hainsworth JD. Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues. Drugs. 1999; 58 Supp3:51-6.
60. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996; 27:149-55.
61. Korones DN, Fisher PG, Cohen KJ, Dubowy RL. No responses to oral etoposide in 15 patients with recurrent brain tumors. Med Pediat Oncol. 2000; 35:80-2.
62. Needle MN, Molloy PT, Ceyer JR, et al. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediat Oncol. 1997; 29:28-32.
63. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999; 17:1516-25.
64. MacDonald D, Cairncross G, Stewart D, et al. Phase II study of topotecan in patients with recurrent malignant glioma. Ann Oncol. 1996; 7:205-7.
65. Brandes AA, Tosoni A, Basso U, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004; 22:4779-86.
66. Gross MW, Altscher R, Brandtner M, et al. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults. Clin Neurol Neurosurg. 2005; 107:207-13.
67. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc. 1994; 69:341-5.
68. Rowinsky EK, Nave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82:1247-59.
69. Vaishampayan U, Parchment RE, Jasti BR, et al. Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology. 1999; 54:822-9.
70. Chang SM, Kuhn JG, Robins HI, et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants. Cancer. 2001; 91:417-22.
71. Terzis AJ, Thorsen F, Heese O, et al. Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer. 1997; 75:1744-52.
72. Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol. 1995; 13:2066-71.
73. Forsyth P, Cairncross G, Stewart D, et al. Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs. 1996; 14:203-6.
74. Postma TJ, Heimans JJ, Luykx SA, et al. A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann Oncol. 2000; 11:409-13.
75. Sanson M, Napolitano M, Yaya R, et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol. 2000; 50:245-9.
76. Rowinsky EK. Taxane analogues: distinguishing royal robes from the "Emperor's new clothes". Clin Cancer Res. 2002; 8:2759-63.
77. Pipas JM, Meyer LP, Rhodes CH, et al. A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol. 2005; 71:301-5.
78. Koukourakis MI, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V. Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation. Int J Radiat Oncol Biol Phys. 1999; 43:107-14.
79. Wehbe T, Glantz M, Choy H, et al. Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas. J Neurooncol. 1998; 39:245-51.
80. Hande KR. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta. 1998; 1400:173-84.
81. Lown JW. Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmac Ther. 1993; 60:185-214.
82. Darling JL, Thomas DG. Response of short-term cultures derived from human malignant glioma to aziridinylbenzoquinone, etoposide and doxorubicin: an in vitro phase II trial. Anticancer Drugs. 2001; 12:753-60.
83. Kaaijk P, Troost D, de Boer OJ, et al. Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas. Brit J Cancer. 1996; 74:187-93.
84. Kuratsu J, Mihara Y, Kochi M, Takaki S, Ushio Y. Antitumor effect of a new anthracyclines derivative, MX2, against human glioma cells. Gan To Kagaku Ryoho. 1989; 16:399-403.
85. Stan AC, Casares S, Radu D, Walter GF, Brumeanu TD. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res. 1999; 19:941-50.
86. Wolff JEA, Trilling T, Mölenkamp G, Egeler RM, Jürgens H. Chemosensitivity of glioma cells in vitro: a meta-analysis. J Cancer Res Clin Oncol. 1999; 125:481-6.
87. Sato Y, Eddy L, Hochstein P. Comparative cardiotoxicity of doxorubicin and a morpholino anthracycline derivative (KRN8602). Biochem Pharmacol. 1991; 42:2283-7.
88. Clarke K, Basser RL, Underhill C, et al. KRN8602 (MX2-Hydrochloride): an active new agent for the treatment of recurrent high-grade glioma. J Clin Oncol. 1999; 17:2579-84.
89. Kuratsu J, Arita N, Kurisu K, et al. A phase II study of KRN8602 (MX2), a novel morpholino anthracyclines derivative, in patients with recurrent malignant glioma. J Neurooncol. 1999; 42:177-81.
90. Kuratsu J, Arita N, Kayama T, et al. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients. J Neurooncol. 2000; 48:145-9.
91. Fabel K, Dietrich J, Hau P, et al. Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 2001; 92:1936-42.
92. Chua SL, Rosenthal MA, Wong SS, et al. Phase II study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neuro-oncol. 2004; 6:38-43.
93. Plowman J, Waud WR, Koutsoukos AD, et al. Preclinical antitumor activity of Temozolomide in mice: efficacy against human brain tumor Xenografts and Synergism with 1,3-Bis (2-chloroethyl)-1-nitrosourea. Cancer Res. 1994; 54:3793-9.
94. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343:1350-4.
95. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6_Methylguanine-DNA Methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004; 10:1871-4.
96. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003.
97. Friedman HS, Kokkinakis DM, Pluda J, et al. Phase I trial of O6-Benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol. 1998; 16:3570-5.
98. Mastronardi L, Puzzilli F, Ruggeri A. Tamoxifen as a potential treatment of glioma. Anticancer Drugs. 1998; 9:581-6.
99. Tallman MS, Wiernik PH. Retinoids in cancer treatment. J Clin Pharmacol. 1992; 32:868-88.
100. Pemrick SM, Lucas DA, Grippo J. The retinoid receptors. Leukemia. 1994; 8:1797-1806.
101. Westarp ME, Westarp MP, Grundl W, Biesalski H, Kornhuber HH. Improving medical approaches to primary CNS malignancies - Retinoid therapy and more. Med Hypotheses. 1993; 41:267-76.
102. Bouterfa H, Picht T, Keb D, et al. Retinoids inhibit human glioma cell proliferation and migration in primary cell cultures but not in established cell lines. Neurosurgery. 2000; 46:419-30.
103. Mukherjee P, Das SK. Action of retinoic acid on human glioblastoma-astrocytoma - 14 cells in culture. Neoplasma. 1995; 42:123-8.
104. Muindi JRF, Young CW, Warrell Jr RP. Clinical pharmacology of all-trans retinoic acid. Leukemia. 1994; 8:1807-12.
105. Phuphanich S, Scott C, Fischbach AJ, Langer C, Yung WKA. All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma. J Neurooncol. 1997; 34:193-200.
106. Yung WKA, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res. 1996; 2:1931-5.
107. Jaeckle KA, Hess KR, Yung WKA, et al. Phase II evaluation of temozolomide and 13-cis retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003; 21:2305-11.
108. Butowski N, Prados MD, Lamborn KR, et al. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma. Int J Radiat Oncol Biol Phys. 2005; 61:1454-9.
109. Magrassi L, Butti G, Pezzotta S, Infuso L, Milanesis G. Effects of vitamin D and retinoic acid on human glioblastoma cell lines. Acta Neurochir. 1995; 133:184-90.
110. Trouillas P, Honnorat J, Bret P, Jouvert A, Gerard JP. Redifferentiation therapy in brain tumors: long-lasting complete regression of gliobastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J Neurooncol. 2001; 51:57-66.
111. Magrassi L, Adorni L, Montorfano G, et al. Vitamin D metabolites activate the sphingomyelin pathway and induce death of glioblastoma cells. Acta Neurochir. 1998; 140:707-14.
112. Baudet C, Chevalier G, Naveilhan P, et al. Cytotoxic effects of 1 alpha, 25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line. Cancer Lett. 1996; 100:3-10.
113. Naveilhan P, Berger F, Haddad K, et al. Induction of glioma cell death by 1,25(OH)2 vitamin D3: towards an endocrine therapy of brain tumors? J Neurosci Res. 1994; 37:271-7.
114. Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol. 1997; 14:1-10.
115. Brown PD. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat. 1998; 52:125-36.
116. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001; 93:178-93.
117. Rémy L. Données récentes sur les métalloprotéinases, acteurs incontournables de la progression tumorale [in French]. Pathol Biol. 1997; 45:759-65.
118. Yip D, Ahmad A, Karapetis CS, Hawkins CA, Harper PG. Matrix metalloproteinase inhibitors: applications in oncology. Invest New Drugs. 1999; 17:387-99.
119. Chintala SK, Tonn JC, Rao JS. Matrix métalloprotéinases and their biological function in human gliomas. Int J Dev Neurosci. 1999; 17:495-502.
120. Thier M, Roeb E, Breuer B, et al. Expression of matrix metalloproteinase-2 in glial and neuronal tumor cell lines: inverse correlation with proliferation rate. Cancer Lett. 2000; 149:63-70.
121. Uhm JH, Dooley NP, Villemure JG, Yong VW. Mechanisms of glioma invasion: role of Matrix-Metalloproteinases. Can J Neurol Sci. 1997; 24:3-15.
122. Brown PD. Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul. 1995; 35:293-301.
123. Brown PD. Clinical studies with matrix metalloproteinase inhibitors. APMIS. 1999; 107:174-80.
124. Rothenberg ML, Nelson AR, Hande KR. New Drugs on the Horizon: Matrix Metalloproteinase Inhibitors. Stem Cells. 1999; 17:237-40.
125. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer. 1996; 32:2528-33.
126. Noha M, Yoshida D, Watanabe K, Teramoto A. Suppression of cell invasion on human malignant glioma cell lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study. J Neurooncol. 2000; 48:217-23.
127. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumour model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res. 1999; 5:845-54.
128. Tonn JC, Kerkau S, Hanke A, et al. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer. 1999; 80:764-72.
129. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Exp Opin Invest Drugs. 2000; 9:2167-77.
130. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of Temozolomide plus the Matrix Metalloproteinase Inhibitor, Marimastat, in recurrent and progressive Glioblastoma Multiforme. J Clin Oncol. 2002; 20:1383-8.
131. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol. 2000; 50:149-63.
132. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359:845-8.
133. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol. 1998; 153:1459-66.
134. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol. 1999; 159:391-400.
135. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999; 274:11721-6.
136. Griscelli F, Li H, Bennaceur-Griscelli A, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA. 1998; 95:6367-72.
137. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res. 2000; 60:2190-6.
138. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998; 58:5686-9.
139. Singhal S, Mehta J. Thalidomide in cancer. BioDrugs. 2001; 15:163-72.
140. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000; 18:708-15.
141. Short SC, Traish D, Dowe A, et al. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol. 2001; 51:41-5.
142. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004; 60:353-7.
143. Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol. 2004; 67: 191-200.
144. Horgan K, Cooke E, Hallett MB, Mansel RE. Inhibition of protein kinase-C mediated signal transduction by tamoxifen. Biochem Pharmacol. 1986; 35:4463-5.
145. Nishizuka Y. Studies and perspectives of protein kinase-C. Science. 1986; 233:305-12.
146. Zhang W, Yamada H, Sakai N, Niikawa S, Nozawa Y. Enhancement of radiosensitivity by tamoxifen in C6 Glioma Cells. Neurosurgery. 1992; 31:725-30.
147. Brandes AA, Ermani M, Turazzi S, et al. Procarbazine and High-Dose Tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study. J Clin Oncol. 1999; 17:645-50.
148. Chamberlain MC, Kormanik PA. Salvage Chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch Neurol. 1999; 56:703-8.
149. Chang SM, Baker II FG, Huhn SI, et al. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma. J Neurooncol. 1998:37:169-76.
150. Couldwell WT, Weiss MH, DeGiorgio CM, et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery. 1993; 32:485-90.
151. Mastronardi L, Puzzilli F, Couldwell WT, Osman FJ, Lunardi P. Tamoxifen and carboplatin combinational treatment of high-grade gliomas. J Neurooncol. 1998; 38:59-68.
152. Muanza T, Shenouda G, Souhami L, et al. High dose tamoxifen and radiotherapy in patients with glioblastoma multiforme: a phase IB study. Can J Neurol Sci. 2000; 27:302-6.
153. Vertosick FT, Selker RG, Pollack IF, Arena V. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of « failed » patients. Neurosurgery. 1992; 30:897-903.
154. Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-Proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery. 1998; 43:124-32.
155. Bredel M, Pollack IF. The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas. Brain Res Rev. 1999; 29:232-49.
156. Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II-preclinical studies in a nude mouse model. Neurosurgery 1999; 45:1208-15.
157. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85:704-10.
158. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90:1473-9.
159. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352:997-1003.